155 related articles for article (PubMed ID: 29632530)
21. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration.
Bae WK; Kang K; Yu JH; Yoo KH; Factor VM; Kaji K; Matter M; Thorgeirsson S; Hennighausen L
FASEB J; 2015 May; 29(5):1653-62. PubMed ID: 25477280
[TBL] [Abstract][Full Text] [Related]
22. EZH2 regulates the expression of p16 in the nasopharyngeal cancer cells.
Zhong J; Min L; Huang H; Li L; Li D; Li J; Ma Z; Dai L
Technol Cancer Res Treat; 2013 Jun; 12(3):269-74. PubMed ID: 23289480
[TBL] [Abstract][Full Text] [Related]
23. The PRC2 complex directly regulates the cell cycle and controls proliferation in skeletal muscle.
Adhikari A; Davie JK
Cell Cycle; 2020 Sep; 19(18):2373-2394. PubMed ID: 32816597
[TBL] [Abstract][Full Text] [Related]
24. Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells.
Koppens MA; Bounova G; Gargiulo G; Tanger E; Janssen H; Cornelissen-Steijger P; Blom M; Song JY; Wessels LF; van Lohuizen M
Gastroenterology; 2016 Oct; 151(4):684-697.e12. PubMed ID: 27342214
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
[TBL] [Abstract][Full Text] [Related]
26. Enhancer of zeste homolog 2 (
Dudakovic A; Camilleri ET; Paradise CR; Samsonraj RM; Gluscevic M; Paggi CA; Begun DL; Khani F; Pichurin O; Ahmed FS; Elsayed R; Elsalanty M; McGee-Lawrence ME; Karperien M; Riester SM; Thaler R; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2018 Aug; 293(33):12894-12907. PubMed ID: 29899112
[TBL] [Abstract][Full Text] [Related]
27. EZH2 Regulates the Developmental Timing of Effectors of the Pre-Antigen Receptor Checkpoints.
Jacobsen JA; Woodard J; Mandal M; Clark MR; Bartom ET; Sigvardsson M; Kee BL
J Immunol; 2017 Jun; 198(12):4682-4691. PubMed ID: 28490575
[TBL] [Abstract][Full Text] [Related]
28. Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.
Grange M; Giordano M; Mas A; Roncagalli R; Firaguay G; Nunes JA; Ghysdael J; Schmitt-Verhulst AM; Auphan-Anezin N
Immunology; 2015 Aug; 145(4):543-57. PubMed ID: 25882552
[TBL] [Abstract][Full Text] [Related]
29. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop.
Béguelin W; Rivas MA; Calvo Fernández MT; Teater M; Purwada A; Redmond D; Shen H; Challman MF; Elemento O; Singh A; Melnick AM
Nat Commun; 2017 Oct; 8(1):877. PubMed ID: 29026085
[TBL] [Abstract][Full Text] [Related]
30. EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy.
Lui JC; Garrison P; Nguyen Q; Ad M; Keembiyehetty C; Chen W; Jee YH; Landman E; Nilsson O; Barnes KM; Baron J
Nat Commun; 2016 Nov; 7():13685. PubMed ID: 27897169
[TBL] [Abstract][Full Text] [Related]
31. CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
Giovannini C; Gramantieri L; Minguzzi M; Fornari F; Chieco P; Grazi GL; Bolondi L
Am J Pathol; 2012 Aug; 181(2):413-22. PubMed ID: 22705236
[TBL] [Abstract][Full Text] [Related]
32. Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation.
Heinen A; Tzekova N; Graffmann N; Torres KJ; Uhrberg M; Hartung HP; Küry P
Glia; 2012 Nov; 60(11):1696-708. PubMed ID: 22821416
[TBL] [Abstract][Full Text] [Related]
33. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
34. Thymocyte proliferation induced by pre-T cell receptor signaling is maintained through polycomb gene product Bmi-1-mediated Cdkn2a repression.
Miyazaki M; Miyazaki K; Itoi M; Katoh Y; Guo Y; Kanno R; Katoh-Fukui Y; Honda H; Amagai T; van Lohuizen M; Kawamoto H; Kanno M
Immunity; 2008 Feb; 28(2):231-45. PubMed ID: 18275833
[TBL] [Abstract][Full Text] [Related]
35. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
36. Distinct mechanisms control human naive and antigen-experienced CD8+ T lymphocyte proliferation.
Migliaccio M; Alves PM; Romero P; Rufer N
J Immunol; 2006 Feb; 176(4):2173-82. PubMed ID: 16455973
[TBL] [Abstract][Full Text] [Related]
37. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
39. Regulation of T Cell Differentiation and Function by EZH2.
Karantanos T; Chistofides A; Barhdan K; Li L; Boussiotis VA
Front Immunol; 2016; 7():172. PubMed ID: 27199994
[TBL] [Abstract][Full Text] [Related]
40. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
